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Background: To evaluate the effects of intravesical administration of paclitaxel (PTX-30W), which was
prepared by solubilization with a water-soluble amphiphilic polymer composed of PMB30W, a copolymer of
2-methacryloyloxyethyl phosphorylcholine and n-butyl methacrylate, in an orthotopic bladder cancer model.
Methods: The cytotoxicities of PMB30W were examined in MBT-2 cell cultures and the results were compared with
those of the conventional paclitaxel solubilizer Cremophor. In an orthotopic MBT-2 bladder cancer model, the effect
of intravesical administration of PTX-30W was compared with that of paclitaxel solubilized with Cremophor
(PTX-CrEL). The paclitaxel concentration in bladder tumors after the intravesical treatment was also evaluated
using liquid chromatography tandem mass spectrometry (LC-MS/MS) system.
Results: In vitro, Cremophor exhibited dose-dependent cytotoxicity towards MBT-2 cells, whereas no cytotoxicity
was observed with PMB30W. In the orthotopic bladder cancer model, intravesical administration of PTX-30W
resulted in a significant reduction of bladder wet weight compared with that of PTX-CrEL. The paclitaxel concentration
in bladder tumors after the intravesical treatment was significantly higher in PTX-30W treated mice than in PTX-CrEL
treated mice.
Conclusions: Intravesically administered PTX-30W can elicit stronger antitumor effects on bladder tumors than
conventional paclitaxel formulated in Cremophor, presumably because of its better penetration into tumor cells.
PTX-30W might be a promising antitumor agent for intravesical treatment of non-muscle invasive bladder cancer.
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Among all newly diagnosed bladder cancer patients, 70%
to 80% of patients are initially diagnosed as having non-
muscle invasive cancers and undergo transurethral resec-
tion, which has a 70% local recurrence rate without any
further adjuvant therapy [1,2]. To prevent recurrence, sur-
gical resection is often followed by adjuvant intravesical* Correspondence: eiji-k@kb3.so-net.ne.jp
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unless otherwise stated.immunotherapy or chemotherapy. As for bladder cancer,
intravesical treatment is attractive. It is because direct
delivery of therapeutic agent into bladder can achieve high
concentration of drug at tumor sites while systemic drug
uptake is limited.
Bacillus Calmette-Guérin (BCG) is currently the most
successful agent for adjuvant intravesical treatment
[3-6]. However, intravesical BCG therapy sometimes
causes local or systemic side effects [7]. Furthermore,
approximately 30% of patients still experience recur-
rence after BCG therapy [1]. Chemotherapeutic agents. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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incidence of side effects is lower compared to BCG ther-
apy, the recurrence rate is still high in intravesical chemo-
therapy [8]. A poor response to intravesical chemotherapy
is thought to be in part due to the poor drug uptake into
the bladder tissue within short indwelling times [9,10].
Intravesically administered drug is typically maintained in
the bladder cavity for 2 hours. Moreover, in a clinical
setting, in some patients, a drug can be held in the bladder
for only a short time because of bladder irritability, and
thus, intravesical treatment can be expected to be only
slightly effective in such patients. Therefore, new agents
which can be delivered more efficiently to the cancer
tissue in the bladder are urgently needed.
Paclitaxel, originally derived from the bark of the Pacific
Yew tree Taxis brevifolia, displays significant antineoplastic
activity against various tumors, including bladder cancer
[11,12]. Due to its poor aqueous solubility, Cremophor
(polyoxyethylated castor oil) is used to dissolve paclitaxel
for clinical use [13]. However, in some patients, Cremo-
phor is often associated with side effects and adverse drug
reactions [14,15]. Moreover, during intravesical treatment,
Cremophor forms micelles in the bladder cavity and
entraps paclitaxel into the micelles. This decrease in the
free fraction of paclitaxel leads to lower drug penetration
into the urothelial mucosa [16].
In this study, to overcome these problems, we used a
polymer composed of 2-methacryloyloxyethyl phos-
phorylcholine (MPC) and n-butyl methacrylate (BMA)
(PMB30W) as a solubilizer for paclitaxel. The PMB30W
is comprised of a 30 mol% hydrophilic MPC unit and a
70 mol% hydrophobic BMA unit. Since the MPC unit is
hydrophilic, PMB30W can be dissolved in water and
form aggregate structure. Also thanks to the hydrophobic
properties of the BMA unit, PMB30W can solubilize
hydrophobic drugs such as paclitaxel. The solubility of
paclitaxel in PMB30W aqueous solution is 1000-fold
higher than that in water [17,18]. PMB30W is also charac-
terized by its nontoxicity and its ability to penetrate
quickly into exposed cells [19,20]. We hypothesized that
the quick penetration of PMB30W into cells would lead to
a higher drug concentration in bladder tumors and result
in favorable cancer control in intravesical treatment.
In the present study, we employed an MBT-2 orthotopic
mouse bladder cancer model which closely mimics the
environments that exist in human bladder cancer. We
previously demonstrated successful implantation of blad-
der tumors after instillation of MBT-2 cells into C3H/
HeN mice with an incidence of almost 100% [21], and we
have been using this novel MBT-2 orthotopic bladder can-
cer model to investigate the therapeutic effects of various
intravesical agents [22-24].
In the present study, the cytotoxicity of blank vehicle
(PMB30W) against MBT-2 cell line was evaluated in vitro.Then, in the orthotopic bladder cancer model, we evalu-
ated the therapeutic effect of intravesically administered
paclitaxel solubilized with PMB30W (PTX-30W) and ex-
amined the paclitaxel concentration in bladder tumors
after intravesical administration of PTX-30W.
Methods
Chemicals
Paclitaxel powder was purchased from Wako Pure Chem-
ical Industries (Osaka, Japan). Cremophor and docetaxel
were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Paclitaxel solubilized with Cremophor (PTX-CrEL)
was obtained from Bristol-Myers Squibb (Tokyo, Japan).
Tumor cell line and animals
MBT-2, which was established from N-[4-(5-nitro-2-
furyl)-2-thiazolyl]-formamide-induced urothelial carcin-
oma of the bladder of a female C3H/HeN mouse, was
maintained in Roswell Park Memorial Institute (RPMI)-
1640 medium containing 10% heat-inactivated fetal bovine
serum at 37°C and 5% CO2.
Eight-week-old female C3H/HeN mice were purchased
from Sankyo Laboratory Service Co (Tokyo, Japan). Mice
were kept under standardized laboratory conditions with
free access to food and water.
Preparation of PTX-30W and PTX-CrEL
The PMB30W was synthesized by a previously described
polymerization technique [18,25]. Fifty mg of PMB30W
was dissolved in 1 ml of phosphate buffered saline (PBS).
Five mg of paclitaxel dissolved in 100 μl of ethanol was
then added to the PBS solution containing PMB30W. The
ethanol was removed by evaporation under reduced
pressure. The resulting paclitaxel concentration was
5.0 mg/ml. It was used following dilution with PBS. For
the Cremophor formulation, paclitaxel was dissolved in
Cremophor: ethanol (1:1, v/v) at a concentration of
6.0 mg/ml and used following dilution with PBS.
LDH assay for determination of cytotoxicity of PMB30W
and Cremophor
To examine the damage to the cell membrane caused by
blank vehicles, lactate dehydrogenase (LDH) assay which
is based on the leakage of LDH from cytosol was carried
out. MBT-2 cells were seeded into 96-well plates at
1.0 × 104 cells/well in 100 μl of RPMI-medium containing
5% fetal bovine serum. After preincubation for 24 hours,
the medium was aspirated and fresh medium containing
varying concentrations of PMB30W and Cremophor was
added. Cells were exposed to the vehicles for 72 hours.
Thereafter, 50 μL of cell-free supernatant was assayed
using CytoTox 96 nonradioactive cytotoxicity assay (Pro-
mega, Madison, WI, USA) according to the manufac-
turer’s protocol, and damage to the cell membrane was
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the absorbance at 490 nm with a microplate reader. The
percentage of LDH release was calculated using the fol-
lowing formula: percentage of release = 100 × (experi-
mental LDH release – spontaneous LDH release)/
(maximal LDH release – spontaneous LDH release).
Spontaneous or maximal LDH release was determined
in the presence of either medium alone or 1% Triton
X-100, respectively. The experiments were repeated
independently three times.Intravesical implantation of MBT-2 cells to establish an
orthotopic bladder cancer model
All of the procedures involving animals and their care in
this study were approved by the Animal Care Committee
of Keio University in accordance with institutional and
Japanese government guidelines for animal experiments.
An orthotopic bladder cancer model was established by
transurethral implantation of MBT-2 cells as previously
described [21]. Briefly, the mice were anesthetized with an
intraperitoneal injection of 1.5 mg/200 μl pentobarbital
sodium. Urine was evacuated from the bladder by apply-
ing mild pressure on the abdomen. A 24-gauge Teflon-
coated catheter was introduced into the lumen of the
bladder through the urethra. MBT-2 cells, 5 × 105 in a
50 μl suspension of serum-free RPMI-1640 medium, were
then injected into the bladder. The catheter was removed,
and to prevent voiding of the MBT-2 cells, the urethra
was tied with 4-0 silk thread for 2 hours.Intravesical PTX-30W administration in an orthotopic
bladder cancer model
The mice were randomly separated into three groups ac-
cording to the agent for intravesical treatment (PBS, PTX-
30W, or PTX-CrEL; n = 9 in each group). PBS was admin-
istered as a control. The total injection volume per animal
was set to 50 μl and the exposure time was set to 30 mi-
nutes. The concentration of paclitaxel in PTX-30W and
PTX-CrEL was fixed at 2 mg/ml. Intravesical drug
administration was performed in the same manner as the
tumor inoculation described above. Each treatment was
repeated 6 times at 2-day intervals starting from day 4
after tumor implantation (on days 4, 7, 10, 13, 16, and 19).
Previously our group has evaluated the pathological find-
ings of bladder tumors in mice sacrificed 3 days after the
instillation of MBT-2 cell suspension, and found the cells
formed tiny superficial tumors, which gradually grew as
apparent visible masses [21]. Therefore, we planned to
start the intravesical treatment on day 4. On day 22, all
mice were sacrificed and underwent necropsy. The blad-
der wet weights were measured to examine the growth of
the bladder tumors.Measurement of paclitaxel concentration in bladder tumors
For the drug uptake study, another set of 22 mice were
prepared and inoculated with MBT-2 cells in the bladder
as described above. On day 20, the mice were divided
into two groups, 12 mice administered PTX-30W and
10 mice administered PTX-CrEL. The concentration of
paclitaxel in the mice administered PTX-30W and PTX-
CrEL was 2 mg/ml and the total injection volume per
animal was set to 50 μl. The mice were sacrificed 30 mi-
nutes after intravesical administration of the drugs. The
bladder was removed from each mouse and the tumor
tissue was harvested. The bladder tumors were vigor-
ously washed three times in 20 ml PBS in order to re-
move any paclitaxel still attached to the tumor surface.
The paclitaxel concentration in the bladder tumors
was analyzed using liquid chromatography tandem mass
spectrometry (LC-MS/MS). The tumor tissues were
weighed and homogenized in 1 ml methanol. The hom-
ogenate was centrifuged at 15000 g for 5 minutes and
the supernatant was recovered as a sample. Volumes of
20 μl of the internal standard (docetaxel, 1000 ng/ml)
and 2 ml of tert-butyl methyl ether were added to each
sample. The samples were then thoroughly vortex
mixed, followed by centrifugation at 1500 g for 5 minutes
at 4°C. The supernatant was transferred and evaporated
to dryness under a stream of nitrogen. The residue was
reconstituted in 0.5 ml of methanol and used for analysis
with the LC-MS/MS system. The LC-MS/MS system
consisted of an UPLC system (Waters, Milford, MA,
USA) and a mass spectrometer (API5000, AB/MDS
Sciex, Framingham, MA, USA). A Cadenza CD-C18
(150 × 2.0-mm inner diameter; 3.0-μm particle size;
Imtakt Corp, Kyoto, Japan) was used as the analytical
column. Samples were eluted using a gradient at a flow
rate of 0.2 ml/min. Mobile phase A was formic acid and
mobile phase B was methanol. For the initial 3.5 minutes
A was 25% and B was 75%, then B was increased to 90%
for the next 3.5 minutes. After that, the initial condition
of A 25% and B 75% was resumed for 2 more minutes
for a total run time of 9 minutes. Paclitaxel was quanti-
fied by monitoring the ion transition of 854→ 286m/z.
Statistical analysis
Values are presented as the mean ± standard error, and
data were analyzed by analysis of variance and the
Mann-Whitney test. Statistical significance was deter-
mined at p < 0.05.
Results
Cytotoxicity of blank vehicles
The cytotoxicity of the blank vehicles (PMB30W and Cre-
mophor) was examined using an LDH assay. As shown in
Figure 1, Cremophor exhibited dose-dependent cytotox-
icity towards MBT-2 cells. In contrast, PMB30W showed
Figure 1 Cytotoxicity of blank vehicles. To determine the cytotoxicity
of blank vehicles, MBT-2 cells were exposed to PMB30W or Cremophor
for 72 hours. The level of LDH released into the culture supernatant
from the cells was measured using LDH assay. PBS was used as control.
The experiments were repeated independently three times. The data
are shown as means ± S.E.
Figure 2 Bladder wet weights after intravesical treatment. Intravesical
administration of PBS, PTX-30W or PTX-CrEL was repeated 6 times at
2 day intervals starting from day 4 after tumor implantation. On day 22,
all mice were sacrificed and underwent necropsy. In the PTX-30W
group, the mean bladder wet weight was 36 ± 5 mg, which was
significantly lower than that in the control group (77 ± 16 mg;
p = 0.0217) and PTX-CrEL group (59 ± 9 mg; p = 0.0469).
Figure 3 Paclitaxel concentration in bladder tumor after intravesical
treatment. After intravesical administration of PTX-30W or PTX-CrEL, the
paclitaxel concentration in bladder tumor was analyzed using
LC-MS/MS. In the PTX-30W group, the paclitaxel concentration in the
bladder tumors was 7719 ± 3274 ng/g, which was significantly higher
than that in the PTX-CrEL group (4905 ± 2412 ng/g; p = 0.0147).
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PMB30W remained non-cytotoxic (data not shown)
whereas Cremophor became too sticky to handle and
place in the wells at a 5% concentration so the cytotoxicity
could not be evaluated.
Antitumor effect of intravesical PTX-30W and PTX-CrEL in
the orthotopic bladder cancer model
Twenty-seven mice were transurethrally inoculated with
5 × 105 MBT-2 cells on day 0 and received intravesical
instillation of control PBS, PTX-30W (2 mg/ml), or
PTX-CrEL (2 mg/ml) on days 4, 7, 10, 13, 16 and 19.
The mice were sacrificed on day 22 and the bladder wet
weights were measured to examine the growth of the
bladder tumors. As shown in Figure 2, intravesical ad-
ministration of PTX-30W resulted in a significant reduc-
tion of bladder wet weight (36 ± 5 mg) as compared with
those of the control group (77 ± 16 mg; p = 0.0217) and
PTX-CrEL group (59 ± 9 mg; p = 0.0469). However, there
was no significant difference in bladder wet weight be-
tween the control group and PTX-CrEL group.
Paclitaxel uptake in bladder tumors
The paclitaxel uptake in bladder tumors after intravesi-
cal administration of paclitaxel formulation was evalu-
ated. Twenty days after transurethral implantation of
MBT-2 cells, PTX-30W (2 mg/ml) or PTX-CrEL
(2 mg/ml) was administered transurethrally into the
bladders of mice. After 30 minutes of administration,
the mice were sacrificed and the amount of paclitaxel
in the bladder tumor tissue was analyzed by LC-MS/
MS. As shown in Figure 3, the paclitaxel concentration
in the bladder tumors was significantly higher in the
PTX-30W treated group than in the PTX-CrEL treated
group (7719 ± 3274 ng/g vs 4905 ± 2412 ng/g; p =
0.0147), indicating that the penetration of intravesicallyadministered PTX-30W into the bladder tumors was
more efficient than PTX-CrEL.
Discussion
To deliver paclitaxel to cancer tissue in the bladder, Cre-
mophor is usually used to solubilize the paclitaxel, how-
ever, it can entrap the drug in micelles, thereby the drug
penetration into the urothelial mucosa is limited [16].
To overcome this limitation of Cremophor, we employed
PMB30W as the vehicle for the delivery of paclitaxel.
The objectives of the present study were to evaluate the
therapeutic effect of intravesically administered PTX-
30W in an orthotopic bladder cancer model and to
investigate the paclitaxel uptake into the bladder tumors.
In an in vitro study, we evaluated the cytotoxicity of the
blank vehicles using LDH assay. Cremophor exhibited
dose-dependent cytotoxicity against the MBT-2 cells
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While the toxicity of Cremophor is not an issue with
respect to cancer cells, it poses a problem in terms of pa-
tient safety since its severe side effects may injure normal
urothelial mucosa, which of course is a concern. Cremo-
phor contains castor oil which is considered to have cyto-
toxicity and a previous study demonstrated that intravesical
administration of Cremophor caused inflammation in non-
tumor bearing bladder tissue [26].
To overcome the limitations associated with using
Cremophor for intravesical treatment, various devices
were developed as solubilizers of paclitaxel in previous
studies. Le Visage et al. [27] prepared polymethylidene
malonate microspheres, which are characterized by the
slow and continuous release of paclitaxel for intravesical
treatment. However, the slow release of paclitaxel means
that most of the encapsulated paclitaxel is voided before
it can be taken up into bladder tissue. On the other hand,
Lu et al. [28] reported the development of paclitaxel-
loaded gelatin nanoparticles which were designed to
release paclitaxel rapidly for intravesical use. However, the
bladder tissue concentrations of paclitaxel after instillation
of the nanoparticles were lower than that of free pacli-
taxel. Rapidly released paclitaxel seems to have been lost
through the first urine void before they were taken up into
the bladder tissue. These previous studies indicate that ef-
ficient drug uptake into bladder mucosa, even within a
short drug indwelling time, is essential for intravesical
chemotherapy.
To investigate the therapeutic effect of intravesically
administered PTX-30W, we used an orthotopic bladder
cancer model, which most closely mimics the clinical
situation of intravesical tumors. Another advantage of
such a model is that an immune-competent animal is
used. To determine the exact antitumor effect induced
by the treatment, immunologic reaction should be taken
into consideration. Thus, a wild-type mouse cancer
model must be used. Our MBT-2 orthotopic bladder
cancer model using wild-type mice is considered to be a
prerequisite for drawing a meaningful conclusion from
our study.
In the present study, we employed the amphiphilic
agent PMB30W as a carrier of paclitaxel. In a previous
in vitro study in living cells, fluorescent-tagged PMB30W
was observed to penetrate across the plasma membrane
and entered the cytoplasm of the cells within a few mi-
nutes [20]. We investigated whether this characteristic of
PMB30W would work advantageously in an orthotopic
bladder cancer model. In the present orthotopic bladder
cancer model, significant bladder tumor suppression was
observed in the intravesical PTX-30W treated group com-
pared with both the PBS control group and the PTX-CrEL
group. Moreover, the uptake study showed significantly
higher paclitaxel concentrations in bladder tumor tissuesin the PTX-30W group than in the PTX-CrEL group
30 minutes after intravesical administration. These results
seem to indicate that the superior antitumor effect of
PTX-30W in orthotopic bladder tumors is attributed to its
efficient uptake into tumor tissue following intravesical
administration. Therefore, PTX-30W was considered to
be suitable for intravesical administration.
Soma et al. [29] evaluated the efficacy of intraperitone-
ally administered PTX-30W in a peritoneal metastasis
model of gastric cancer in nude mice. They demon-
strated that intraperitoneal administration of PTX-30W
could suppress peritoneal metastasis more effectively
than PTX-CrEL, presumably because of its better pene-
tration into the disseminated peritoneal tumors. Their
study findings are in agreement with those of the present
study with regards to the point that PTX-30W is super-
ior in intracavitary treatment in which the administered
agents can be delivered directly at a high concentration
to the tumor lesion, however, what makes our study
different from theirs is the drug exposure time. While
intraperitoneally administered drug is allowed to contact
tumor tissues until it is absorbed from the cavity, intra-
vesically administered drug can contact tumor tissues
only until it is flushed out from the cavity by urination.
Because of the disadvantage of the short exposure time,
multiple instillations of PTX-30W were planned in the
first set of experiment and the results showed that the
intravesically administered PTX-30W could significantly
suppress bladder tumor growth and exhibited better
drug uptake compared with PTX-CrEL. One limitation
of the present study is that we did not evaluate the cor-
relation of the tumor concentration of PTX-30W with
tumor size. However, we believe that a high drug con-
centration after a single instillation of PTX-30W had an
effect on the antitumor activity of the drug.
Conclusion
We have shown that intravesical PTX-30W treatment
exhibits significant tumor suppression in an orthotopic
bladder cancer model compared to conventional PTX-
CrEL and that efficient penetration of the PTX-30W
into tumor tissue seemed to be associated with its anti-
tumor effect. The results of the present study indicate
that intravesical PTX-30W treatment may be a promis-
ing new therapy for non-muscle invasive bladder cancer.
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